Amgen, Neumora Partner to Develop Precision Therapies for ALS

Amgen, Neumora Partner to Develop Precision Therapies for ALS

309290

Amgen, Neumora Partner to Develop Precision Therapies for ALS

Amgen and Neumora Therapeutics announced that they are collaborating to develop precision therapies for amyotrophic lateral sclerosis (ALS) and other brain diseases. The partnership will leverage each of the company’s expertise, with the goal of bringing to the market effective therapies targeted at those patients most likely to respond to them. Specifically, it will leverage Neumora’s precision neuroscience platform and Amgen’s deCODE genetics to identify genetic risk factors for diseases like ALS and schizophrenia. Recommended Reading…

You must be logged in to read/download the full post.